TY  - JOUR
TI  - Key concepts in biosimilar medicines:
What physicians must know
AB  - Biologics’ are a class of medications produced by living cells using recombinant DNA technology. Biologics have had an important
impact in many areas of medicine, and in particular in rheumatology and oncology. However, the high cost of these
agents is a growing concern, particularly as more products become available and their use for the treatment of immunemediated
inflammatory diseases continues to expand. Biosimilars, also called follow-on biologics, have been viewed as a potential
cost-saving alternative to traditional therapies. Currently, a product can be considered biosimilar to a reference product
if there are no clinically meaningful differences in terms of safety, purity, and potency. In this review, the most important key
concepts about biosimilars were summarized for physicians emphasizing the status in Turkey.
AU  - Iskit, Alper B.
DO  - 10.14744/nci.2021.84669
PY  - 2022
JO  - İstanbul Kuzey Klinikleri
VL  - 9
IS  - 1
SN  - 2148-4902
SP  - 86
EP  - 91
DB  - TRDizin
UR  - http://search/yayin/detay/522578
ER  -